UGAZF is an emerging pharmaceutical company that is expected to grow to $4.5 billion by 2024. If you’re interested in investing in this stock, you should know a few things before you start. The beta of this stock is 6.23 and the R-squared is 27%. Moreover, it has a standard deviation of 227.3%, and the volatility is low at around 8%. Nevertheless, it’s possible to lose a lot of money by investing in this stock if you’re not careful.
If you’re thinking of buying UGAZF stock but you’re not sure where to start, you can start by learning more about the company and its stock chart. From there, you can start comparing the price of UGAZF to other stocks in the same industry. This can help you determine whether UGAZF is worth your time and money.
UGAZF
In the past year, UGAZF stock has returned -79.3%, and over the last three years it has returned -64.4%. The stock has lost an average of -68.6% annually, and over the last decade, it has lost an average of -67.8%. The stock has a beta of 6.23 and an R-squared of 27%. However, this low beta and high standard deviation mean that UGAZF carries a high level of risk.
UGAZF stock
If you want to invest in UGAZF stock, there are several factors you should know. First, you should look at the performance of the stock. Its return over the past year has been -79.3%, and its return over the past three, five, and ten years have been -64.4% and -67.0%, respectively. Additionally, the stock has a beta of 6.23 and a total risk rating of HIGH.
UGAZF stock chart
UGAZF stock chart can be viewed online at Nasdaq. The chart features an interactive, downloadable history data table. The chart can be accessed via the navigation toolbar. If you are having trouble viewing it, try disabling third-party cookie blocking or clearing your cache.
UGAZF stock price
If you are interested in buying shares of UGAZF stock, you can start by learning more about the company. Its stock has an expense ratio of 1.65%. Its return on equity is -79.3% over the past year, and it has a five-year average return of -64.4%. In addition, it has a beta of 6.23 and a standard deviation of 227.3%, making it a high-risk investment.
UGAZF has an R-squared of 27%, a beta of 6.23, and a standard deviation of 227.3%
A correlation coefficient is a measure of the relationship between two variables. A correlation coefficient is the measure that shows how much variation in one variable is explained by variation in another. The coefficient of determination is a numerical measure of that relationship and is typically expressed as a percentage or decimal number. It is most frequently used in statistical analyses, and is the percentage of variation in a dependent or predicted variable explained by variations in the independent variable.
UGAZF has a standard deviation of 227.3%
UGAZF is a gas-related ETN that was launched in 2012. It is managed by the Management Team at Credit Suisse AG. Its primary benchmark is the S&P GSCI Natural Gas ER USD index. It seeks to replicate, net of expenses, three times the performance of this index. The fund consists of futures contracts on a single commodity, natural gas. The expense ratio is 1.65%.
